GlassScriptPhysician profile
Harmeet Kaur
NPI 1417575671
$2,205.98
in general payments reported to CMS, 2019-2025
17 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $605 · 2023: $421 · 2024: $648 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $493.12 | 2022-2024 | Qelbree, Qelbree |
| Abbvie INC. | $439.81 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $202.65 | 2021-2022 | |
| Corium, LLC | $153.36 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $141.25 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $137.76 | 2022-2025 | Invega, Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $104.85 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $98.79 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $83.36 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $69.80 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $56.39 | 2022-2024 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $54.63 | 2021-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $48.78 | 2023-2024 | Auvelity |
| Brainsway USA INC | $45.63 | 2023-2024 | Brainsway Deep Tms System |
| Ironshore Pharmaceuticals INC. | $37.23 | 2023-2024 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $24.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmeet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.